ARDX Strong upgrade from a top financial firm
Mis à jour
ARDX Ardelyx is a biopharmaceutical company that discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the US and internationally.
On 3/2/2022 Jefferies Financial Group Upgraded ARDX from Hold to Buy raising the price target from $1.00 to $5.00
This would be a 581% gain from the current level.
Looking forward to read your opinion about it.
On 3/2/2022 Jefferies Financial Group Upgraded ARDX from Hold to Buy raising the price target from $1.00 to $5.00
This would be a 581% gain from the current level.
Looking forward to read your opinion about it.
Trade fermée: cible de profit atteinte
Target reached! 6X gain!
BUYSELL indicators tradingindicators.store/
TRADING COURSE bit.ly/tradex
Private Signals patreon.com/PremiumOptionsSignals
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
TRADING COURSE bit.ly/tradex
Private Signals patreon.com/PremiumOptionsSignals
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.